Cubist Pharms Llc Company Profile

✉ Email this page to a colleague

CUBIST PHARMS LLC has six approved drugs.

There are twenty-nine US patents protecting CUBIST PHARMS LLC drugs.

There are three hundred and forty-one patent family members on CUBIST PHARMS LLC drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	7,906,489*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	8,859,510*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes	9,988,406	⤷ Try a Trial	Y			⤷ Try a Trial
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	8,058,238	⤷ Try a Trial
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	6,468,967	⤷ Try a Trial
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	6,852,689	⤷ Try a Trial
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	8,058,238	⤷ Try a Trial
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	5,912,226	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2008-11-19
➤ Subscribe	Tablets	200 mg	➤ Subscribe	2015-05-27

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Australia	2004299413	⤷ Try a Trial
Eurasian Patent Organization	028342	⤷ Try a Trial
Russian Federation	2478643	⤷ Try a Trial
European Patent Office	2753326	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2005058886	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1115417	06C0022	France	⤷ Try a Trial	PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
1115417	SZ 22/2006	Austria	⤷ Try a Trial	PRODUCT NAME: DAPTOMYCIN
1556389	602	Finland	⤷ Try a Trial
1556389	CR 2016 00004	Denmark	⤷ Try a Trial	PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
1539977	C201530022	Spain	⤷ Try a Trial	PRODUCT NAME: FIDAXOMICINA; NATIONAL AUTHORISATION NUMBER: EU/1/11/733/001-004; DATE OF AUTHORISATION: 20111207; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/733/001-004; DATE OF FIRST AUTHORISATION IN EEA: 20111207
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.